MUVON Therapeutics is a Swiss clinical-stage biotechnology company that aims to revolutionize the treatment of various diseases based on muscle degeneration and damage by using the body’s own cells. Our first therapeutic focus is the treatment of stress urinary incontinence in women (phase II) and men (preclinical).